Lima D R, Santos R M, Werneck E, Andrade G N
Research Unit, Clinical Pharmacology Institute, Rio de Janeiro, Brazil.
Eur J Drug Metab Pharmacokinet. 1991 Jul-Sep;16(3):161-70. doi: 10.1007/BF03189954.
The effects of misoprostol and cimetidine on diazepam pharmacokinetics were evaluated in order to determine whether the kinetic variables for diazepam and nordiazepam alone differ with the repeated oral administration of misoprostol and cimetidine to healthy adult volunteers. The trial was conducted as an open crossover study in 12 normal subjects, divided into two groups with all subjects receiving both regimens. Total study duration was 5 weeks. An initial clinical assessment, including blood biochemistry and assessment of subject oxidation status was carried out on study day 1. On this day, subjects began taking diazepam (10 mg) orally for one week, with pharmacokinetic studies performed at day 8, when steady state levels of diazepam were reached. This was followed by one week with active drug, misoprostol to Group I and cimetidine to Group II, with pharmacokinetic studies performed at the end of a 1-week treatment. After a 2-week wash-out period, both groups took for one week, the alternate drug, i.e. cimetidine plus diazepam to Group I and misoprostol plus diazepam to Group II. On days 8, 15 and 36, subjects were admitted to the hospital for 12 h, during which time a clinical examination was carried out and blood samples were taken at time zero and at 4, 8, 12, 24, and 36 h post-dosing for the measurement of serum diazepam and nordiazepam. The main parameters measured and evaluated were diazepam and nordiazepam pharmacokinetics at steady state (days 8, 15 and 36). These were areas under the curve in the dose intervals (AUC0-24h), maximum plasma concentrations (Cmax), time to peak concentrations (Tmax), elimination half-life (t1/2), elimination constant (Kel), distribution volume (Vd), total body clearance (ClB) and clearance after oral administration (Cloral). The results demonstrated that plasma diazepam and nordiazepam concentrations had a significant increase after steady states have been reached with the simultaneous administration of 800 mg of cimetidine daily for one week. The simultaneous administration of 800 micrograms of misoprostol did not cause any significant change in diazepam and nordiazepam plasma levels after steady states had been reached. Comparing the pharmacokinetic parameters of Groups A and B as well as within groups on days 8, 15 and 36, a significant increase in plasma diazepam and nordiazepam levels was detected. This was due to a cimetidine-induced impairment in microsomal oxidation of diazepam and nordiazepam, which caused a decrease in total metabolic clearance and increased mean steady state plasma concentrations. A more prolonged half-life was observed for both groups taking cimetidine as well as an increase of mean maximum plasma concentrations.(ABSTRACT TRUNCATED AT 400 WORDS)
评估米索前列醇和西咪替丁对地西泮药代动力学的影响,以确定在健康成年志愿者反复口服米索前列醇和西咪替丁的情况下,单独使用地西泮和去甲地西泮的动力学变量是否存在差异。该试验作为一项开放交叉研究,在12名正常受试者中进行,分为两组,所有受试者均接受两种治疗方案。总研究持续时间为5周。在研究第1天进行了初步临床评估,包括血液生化检查和受试者氧化状态评估。在这一天,受试者开始口服地西泮(10毫克),持续一周,在第8天进行药代动力学研究,此时达到地西泮的稳态水平。接下来的一周,第一组服用活性药物米索前列醇,第二组服用西咪替丁,并在1周治疗结束时进行药代动力学研究。经过2周的洗脱期后,两组服用交替药物1周,即第一组服用西咪替丁加地西泮,第二组服用米索前列醇加地西泮。在第8、15和36天,受试者入院12小时,在此期间进行临床检查,并在给药后0、4、8、12、24和36小时采集血样,以测定血清地西泮和去甲地西泮。测量和评估的主要参数是稳态时(第8、15和36天)地西泮和去甲地西泮的药代动力学。这些参数包括剂量间隔内的曲线下面积(AUC0-24h)、最大血浆浓度(Cmax)、达峰时间(Tmax)、消除半衰期(t1/2)、消除常数(Kel)、分布容积(Vd)、总体清除率(ClB)和口服清除率(Cloral)。结果表明,在每天同时服用800毫克西咪替丁一周达到稳态后,血浆地西泮和去甲地西泮浓度显著升高。在达到稳态后,同时服用800微克米索前列醇未导致地西泮和去甲地西泮血浆水平发生任何显著变化。比较第8、15和36天A组和B组以及组内的药代动力学参数,发现血浆地西泮和去甲地西泮水平显著升高。这是由于西咪替丁导致地西泮和去甲地西泮微粒体氧化受损,从而导致总代谢清除率降低,平均稳态血浆浓度升高。服用西咪替丁的两组均观察到半衰期延长以及平均最大血浆浓度增加。(摘要截短至400字)